Streetbeat News

Analyst Ratings

IOVA

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating on Iovance Biotherapeutics (NASDAQ:IOVA) and maintained a $38 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:29 am

ARWR

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on Arrowhead Pharma (NASDAQ:ARWR) and maintained a $90 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:26 am

TBLA

Taboola.com (NASDAQ:TBLA) reported Q2 earnings of $0.00 per share, beating the analyst consensus estimate of $(0.05) by 106 percent. This is a 95 percent decrease from last year's earnings. The company also reported quarterly sales of $332.00 million, beating the analyst consensus estimate of $315.44 million by 5.25 percent, but a 3.12 percent decrease from last year's sales.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2023 | 10:25 am

JANX

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:24 am

ITOS

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on ITeos Therapeutics (NASDAQ:ITOS) but lowers the price target from $54 to $44.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:23 am

PSNL

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a 'Buy' rating on Personalis (NASDAQ:PSNL) but lowers the price target from $10 to $7.5.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:22 am

XOMA

HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on XOMA (NASDAQ:XOMA) and raises the price target from $69 to $74.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:21 am

BLNK

HC Wainwright & Co. analyst Sameer Joshi has reiterated a 'Buy' rating on Blink Charging (NASDAQ:BLNK) and maintained a $50 price target.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:19 am

CIFR

HC Wainwright & Co. analyst Mike Colonnese maintains a 'Buy' rating on Cipher Mining (NASDAQ:CIFR) and raises the price target from $3 to $4.5.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:17 am

PRAX

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Praxis Precision Medicine (NASDAQ:PRAX) and maintained a price target of $15.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 10:16 am